fashion -WSS

fashion

author：comprehensive 2025-10-01 00:58:40 - browse：1823

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Pumping milk in bathrooms at health conferences is common

focus

WSS

Morphosys mixed study results for blood cancer drug

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Pumping milk in bathrooms at health conferences is common

Pumping milk in bathrooms at health conferences is common

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

FDA sets aggressive timeline for overhauling inspection procedures

explore

fashion

focus

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Activists slam private health insurers over coverage restrictions

Cardiologists urge adding sexual orientation, gender identity to health records

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Maisha Meds is a PBM, but don't call it that

Anesthesiologist group: stop taking Ozempic before surgery

Dana Farber says 6 studies to be retracted and 31 corrected

As demand for Covid shots wanes, Moderna seeks its next success

Update the Apgar Score to remove skin color

focus

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Maisha Meds is a PBM, but don't call it that

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Inaction leaves children at risk from dangerous chemotherapy drug

There's an unseen cost to disruptive road

Ransomware attacks on hospitals: Study outlines patient impact

explore

leisure time

focus

entertainment